![Child receiving child-friendly antimalarial  treatment in Kenya.](/sites/novartis_com/files/styles/webp/public/2021-07/malaria-factsheet-preview-image.jpg.webp?itok=F8JPVBxl "Child receiving child-friendly antimalarial  treatment in Kenya.") 

Description

Novartis has been in the front ranks of a revolution in the treatment of malaria, launching the first fixed-dose artemisinin-based combination therapy (ACT) in 1999 and the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV) in 2009.



 

 

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.



 

 [ Download (PDF 252.62 KB)  ](https://www.novartis.com/sites/novartis_com/files/novartis-malaria-factsheet-2022.pdf)